Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat scheduled for February 6, 2025, at 1:30 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through Mersana's website (www.mersana.com) in the Investors & Media section. The recorded session will remain available for approximately 90 days after the event.
Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica specializzata in conjugati anticorpo-farmaco (ADC) per il trattamento del cancro, ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. La direzione dell'azienda parteciperà a una conversazione informale in programma per il 6 febbraio 2025, alle 13:30 EST.
Investitori e parti interessate possono accedere a un webcast live della presentazione attraverso il sito web di Mersana (www.mersana.com) nella sezione Investitori & Media. La registrazione della sessione sarà disponibile per circa 90 giorni dopo l'evento.
Mersana Therapeutics (NASDAQ: MRSN), una empresa biofarmacéutica en fase clínica especializada en conjugados anticuerpo-fármaco (ADC) para el tratamiento del cáncer, ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. La dirección de la empresa participará en una charla informal programada para el 6 de febrero de 2025, a la 1:30 p.m. ET.
Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través del sitio web de Mersana (www.mersana.com) en la sección de Inversores y Medios. La sesión grabada estará disponible durante aproximadamente 90 días después del evento.
Mersana Therapeutics (NASDAQ: MRSN), 임상 단계의 생물 제약 회사로 항체-약물 접합체 (ADC)를 전문으로 하며, 암 치료를 위한 구겐하임 SMID 캡 생명공학 회의에 참여한다고 발표했습니다. 회사의 경영진은 2025년 2월 6일 오후 1시 30분 ET에 예정된 대담에 참여할 것입니다.
투자자 및 관심 있는 당사자는 Mersana의 웹사이트 (www.mersana.com) 투자자 및 미디어 섹션을 통해 발표의 실시간 웹캐스트에 접근할 수 있습니다. 녹화된 세션은 이벤트 후 약 90일 동안 이용 가능합니다.
Mersana Therapeutics (NASDAQ: MRSN), une entreprise biopharmaceutique en phase clinique spécialisée dans les conjugués anticorps-médicaments (ADC) pour le traitement du cancer, a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference. La direction de l'entreprise participera à une discussion informelle prévue pour le 6 février 2025 à 13h30 ET.
Les investisseurs et parties intéressées peuvent accéder à un webinaire en direct de la présentation via le site web de Mersana (www.mersana.com) dans la section Investisseurs & Médias. La session enregistrée sera disponible pendant environ 90 jours après l'événement.
Mersana Therapeutics (NASDAQ: MRSN), ein klinisches biopharmazeutisches Unternehmen, das auf Antikörper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung spezialisiert ist, hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference bekannt gegeben. Das Management des Unternehmens wird an einem geplanten Feuerstuhlgespräch am 6. Februar 2025 um 13:30 Uhr ET teilnehmen.
Investoren und Interessierte können über die Website von Mersana (www.mersana.com) im Abschnitt Investoren & Medien auf ein Live-Webcast der Präsentation zugreifen. Die aufgezeichnete Sitzung wird für etwa 90 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana’s website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When is Mersana Therapeutics (MRSN) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors access Mersana's (MRSN) Guggenheim Conference presentation?
How long will the replay of MRSN's Guggenheim Conference presentation be available?
What is Mersana Therapeutics' (MRSN) main focus in cancer treatment?
